Can Multiple Myeloma Be Cured? Understanding Functional Cure and 2026 Breakthroughs
Clinical Outcomes & Curability · A Guide for Patients and Families
Medical Disclaimer: The following content is compiled based on the latest authoritative guidelines at home and abroad. It is for reference only for patients and their families and cannot replace the professional medical advice of the attending physician. Please be sure to follow the doctor's advice for the treatment plan.
Foreword: Key Takeaways for Patients and Families
"Doctor, can multiple myeloma be completely cured?" "My test results are entirely normal now—am I cured?" "Will I ever be able to stop medications and live a normal life?"
In myeloma care, "cure" is the single most anticipated and frequently asked question. Today, modern hematology provides an objective, evidence-based, and deeply encouraging answer:
- In classical textbooks, Multiple Myeloma (MM) is still categorized as incurable. However, the clinical definition of "cure" has undergone a profound transformation.
- Modern oncology is actively pursuing a "Functional Cure" (or Operational Cure). By utilizing anti-CD38 monoclonal antibody quadruplets, stem cell transplantation, CAR T-cell therapies, and bispecific antibodies, physicians can now suppress malignant clones down to microscopic levels, allowing patients to achieve durable, decades-long remissions with normal life expectancy, excellent quality of life, and treatment-free intervals.
- "Sustained MRD Negativity" is the definitive surrogate for long-term survival. Following the historic unanimous approval by the U.S. FDA ODAC in April 2024, achieving and sustaining undetectable minimal residual disease (10⁻⁵ to 10⁻⁶) is widely recognized as the gateway to a functional cure.
1. Traditional Paradigm vs. The 2026 "Functional Cure"
To understand whether myeloma can be cured, one must distinguish between conventional hematologic response and true deep cellular clearance.
1.1 Why a "Complete Response" (CR) Is Not Equivalent to a Cure
Under standard International Myeloma Working Group (IMWG) criteria, a Complete Response (CR) is defined as:
- Negative immunofixation on both serum and urine;
- Complete disappearance of any soft-tissue plasmacytomas;
- Less than 5% plasma cells in bone marrow aspirates.
The Microscopic Gap in Standard CR At initial diagnosis, an active myeloma patient typically harbors approximately 1 trillion (10¹²) malignant plasma cells. Achieving a conventional CR reduces the tumor burden below the detection threshold of standard electrophoresis, but can still leave up to 1 billion (10⁹) viable myeloma cells hiding in the bone marrow. This residual reservoir—termed Minimal/Measurable Residual Disease (MRD)—is the primary source of eventual disease relapse.
1.2 Defining the Modern "Functional Cure" (Operational Cure)
Because eradicating literally every single clone is biologically challenging, leading international authorities (including the International Myeloma Foundation, IMF) focus on Functional Cure:
Clinical Pathway to 'Functional Cure' & Treatment Cessation
The scientific evolution from deep cellular clearance to long-term disease-free survivorship
Core Pillars of a Functional Cure:
- Profound and Durable Clonal Dormancy: Residual malignant cells are suppressed to undetectable levels and rendered quiescent.
- Extended Progression-Free Survival (PFS): Patients remain progression-free for 5, 10, 15, or more years after initial therapy.
- Preserved Organ Function & Normal Quality of Life: Zero myeloma-related bone destruction, renal impairment, anemia, or hypercalcemia (CRAB symptoms).
- Treatment-Free Intervals (TFI): Under stringent MRD-guided surveillance, eligible patients can safely stop continuous therapy and live medication-free.
Literature References: NCCN Guidelines v5.2026, Multiple Myeloma; IMWG Consensus Criteria for Response and Minimal Residual Disease
2. Sustained MRD Negativity: The Gold Standard Benchmark
Minimal Residual Disease (MRD) status represents the single most powerful prognostic biomarker in modern multiple myeloma management.
2.1 Standardized IMWG MRD Criteria
| MRD Category | Technical Definition | Sensitivity Threshold | Plain-Language Takeaway |
|---|---|---|---|
| Flow MRD-Negative | Absence of phenotypically aberrant clonal plasma cells via Next-Generation Flow (NGF / EuroFlow) on bone marrow aspirates. | 1 in 10⁵ nucleated cells (10⁻⁵) or higher | Highly sensitive cellular scan of the bone marrow. |
| Sequencing MRD-Negative | Absence of clonal DNA sequences via Next-Generation Sequencing (NGS / LymphoSIGHT) on bone marrow aspirates. | 10⁻⁵ to 10⁻⁶ (< 2 identical clonal reads) | Ultra-deep genetic search for any residual cancer DNA. |
| Imaging Plus MRD-Negative | Bone marrow MRD negativity (by NGF or NGS) plus complete resolution of all hypermetabolic areas on ¹⁸F-FDG PET-CT (SUV lower than mediastinal blood pool). | Multi-modal: Marrow + Whole-body metabolic clearance | Proves both the bone marrow and body tissues are metabolically clear. |
| Sustained MRD-Negative | Confirmation of marrow and imaging MRD negativity at two consecutive time points at least 1 year (12 months) apart. | Longitudinal durability (e.g., 2-year or 5-year sustained MRD-) | The true gateway to long-term survival and potential drug-free holidays. |
2.2 The Historic April 12, 2024 FDA ODAC Milestone
FDA ODAC Unanimous Vote (12–0) On April 12, 2024, the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted unanimously (12 to 0) to approve MRD negativity as an accelerated approval surrogate endpoint in clinical trials for multiple myeloma.
Backed by the global EVIDENCE meta-analysis, data confirmed that achieving deep MRD negativity directly translates into dramatic, statistically validated extensions in overall survival (OS) and progression-free survival (PFS), fundamentally accelerating the delivery of potentially curative drugs to patients worldwide.
2.3 Overcoming High-Risk Cytogenetic Abnormalities
Historically, patients with high-risk cytogenetics—such as del(17p), t(4;14), t(14;16), or 1q21 gain/amplification—faced poor prognoses. Landmark clinical trials have now demonstrated that achieving sustained 10⁻⁵ or 10⁻⁶ MRD negativity completely overcomes the adverse prognostic impact of high-risk cytogenetics, aligning their long-term survival curves with those of standard-risk patients.
Literature References: Chinese Guidelines for the Diagnosis and Management of Multiple Myeloma (2024 Revision); FDA ODAC Recommendation (2024)
3. Frontline Quadruplets & ASCT: Maximizing Clearance at the Starting Line
The integration of anti-CD38 monoclonal antibodies (daratumumab / isatuximab) into frontline regimens alongside autologous stem cell transplantation (ASCT) has pushed initial MRD clearance rates to unprecedented heights.
Key Frontline Trial Evidence:
- PERSEUS Trial (Transplant-Eligible NDMM; Dara-VRd vs. VRd):
- At 47.5 months median follow-up, 4-year PFS was 84.3% with Dara-VRd vs. 67.7% with VRd (HR = 0.42, P < 0.001), representing a 58% reduction in the risk of progression or death.
- Rate of ≥ CR reached 87.9% vs. 70.1%; bone marrow MRD negativity (10⁻⁶) reached 65.1% vs. 32.2%; sustained MRD negativity (≥ 12 months) was 64.8% vs. 29.7%.
- MAIA Trial (Transplant-Ineligible NDMM; Dara-Rd vs. Rd):
- Median PFS reached an unprecedented 61.9 months (over 5.1 years) vs. 34.4 months for Rd alone (HR = 0.55, P < 0.0001).
- 5-year overall survival (OS) was 66.6% vs. 53.6% (HR = 0.66, P = 0.0003). Continuous Dara-Rd deepened responses over time, with MRD-negativity rates more than doubling from 12.8% at 12 months to 31.8% at 60 months.
- CEPHEUS Trial (Transplant-Ineligible/Deferred NDMM; Dara-VRd vs. VRd):
- In 395 patients, overall 10⁻⁵ MRD negativity was 60.9% with Dara-VRd vs. 39.4% with VRd (P < 0.0001), and sustained MRD negativity (≥ 12 months) reached 48.7% vs. 26.3%.
- MANHATTAN & IsKia Studies (Carfilzomib-Based Quadruplets):
- In the MANHATTAN trial, Dara-KRd induction enabled 1-year PFS and OS of 98% and 100%.
- In the IsKia trial (Isa-KRd), post-consolidation 10⁻⁶ ultra-deep MRD negativity reached 67% in Isa-KRd vs. 48% in KRd, including 72% in high-risk patients.
Literature References: PERSEUS trial, NEJM 2024; MAIA trial, NEJM / Lancet Oncol; IsKia trial, Lancet 2024
4. Cellular Immunotherapies: Curative Potential in Relapsed/Refractory Disease
In heavily pretreated and multi-refractory multiple myeloma, T-cell redirecting therapies—specifically chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs)—have produced remarkable, long-lasting remissions.
CAR T-Cell Therapy: Curative Potential in Relapsed/Refractory Myeloma
Single infusion delivering deep, durable remissions and long-term survivorship
Comprehensive Clinical Trial Benchmark:
| Immunotherapy | Trial & Study Population | Overall Response (ORR) / CR Rate | MRD Negativity Rate (10⁻⁵) | Long-Term Survival Outcomes | Functional Cure Impact |
|---|---|---|---|---|---|
| Ciltacabtagene Autoleucel (Cilta-cel / Carvykti) | CARTITUDE-1 (Median 6 prior lines, median follow-up 61.3 mo) | ORR 97.9%, sCR 82.5% | 92% evaluable patients achieved MRD- | Median OS reached 60.7 months (over 5 years) | 33% of patients remained in continuous remission for ≥ 5 years without any maintenance therapy, demonstrating proof-of-concept for operational cure. |
| Cilta-cel (Early Relapse) | CARTITUDE-4 (1–3 prior lines, Len-refractory) | ORR 84.6% vs. 67.3% (SoC) | 60.6% vs. 15.6% (10⁻⁵ NGS) | 30-month OS was 76.4% vs. 63.8% (HR = 0.55) | First CAR-T to demonstrate statistically significant OS superiority in a randomized phase 3 trial (PFS HR = 0.29). |
| Zevorcabtagene Autoleucel (Zevor-cel) | LUMMICAR-1 (Heavily pretreated, median follow-up 53.3 mo) | ORR 100%, ≥ CR 78.6% | 100% in surviving CR/sCR patients | 5-year Overall Survival (OS) reached 76.9% | Demonstrates robust long-term survivorship across extensive clinical follow-up. |
| Anitocabtagene Autoleucel (Anito-cel / D-Domain) | iMMagine-1 (Novel synthetic D-domain binder) | ORR 96%, sCR/CR 74% | 93% in evaluable patients (10⁻⁵) | 18-month OS rate 90%; 18-month PFS rate 66% | Designed for "fast-on/fast-off" binding to avoid T-cell exhaustion and minimize neurotoxicity. |
| AZD0120 (GC012F) (Dual BCMA/CD19) | Frontline Consolidation (NDMM, 36.5 mo follow-up) | ORR 100%, sCR 97% | 100% achieved 10⁻⁶ MRD- (81.5% sustained > 12 mo) | 30-month PFS 88%; 30-month OS 92% | Dual-targeting stem cell elimination in frontline settings achieves exceptional depth. |
| Teclistamab (BCMA × CD3 BsAb) | MajesTEC-1 (Multi-refractory RRMM) | ORR 63.0%, ≥ CR 39.4% | 85.7% in evaluable patients | Median PFS 11.4 to 17.2 months | Off-the-shelf availability allows immediate intervention without manufacturing delay. |
| Talquetamab (GPRC5D × CD3 BsAb) | MonumenTAL-1 (Triple-class exposed RRMM) | ORR 70.0%, ≥ CR 35.0% | 65%~70% in evaluable patients | Median DOR 10.2 months; durable responses post-BCMA | Provides an alternative non-BCMA target, effectively overcoming antigen-loss escape. |
Literature References: CARTITUDE-1/4, NEJM / Lancet; LUMMICAR-1, ASCO/ASH; MajesTEC-1, NEJM; MonumenTAL-1, NEJM
5. The Horizon of Treatment Discontinuation (Treatment-Free Intervals)
Historically, myeloma maintenance was prescribed indefinitely until disease progression or intolerable toxicity. In 2026, clinical paradigms are shifting toward MRD response-adapted, fixed-duration therapies.
5.1 Prospective Clinical Evidence for Stopping Treatment
- PERSEUS Protocol-Defined De-escalation: In the phase 3 PERSEUS trial, patients in the Dara-VRd arm who achieved ≥ CR and sustained MRD negativity for at least 12 months (after ≥ 24 months of maintenance) successfully discontinued daratumumab, continuing on lenalidomide monotherapy without loss of disease control.
- The MASTER Trial: Under a response-adapted framework, patients receiving Dara-KRd and ASCT stopped therapy after achieving two consecutive bone marrow and imaging MRD-negative confirmations (10⁻⁵), entering a durable treatment-free observation window.
- The MRD2STOP Study: A dedicated multicenter trial evaluating the cessation of maintenance therapy guided by multi-modal MRD negativity (NGS 10⁻⁶ + PET-CT), demonstrating that standard-risk patients with sustained negativity can safely discontinue maintenance without early recurrence.
Clinical Safety Consensus International myeloma working groups (such as the IMWG and SMSG) emphasize that stopping standard maintenance therapy based on MRD status alone should strictly occur within the context of clinical trials or under the close guidance of an experienced myeloma specialist. Outside of structured monitoring, spontaneous unmonitored cessation is strongly discouraged.
Literature References: MASTER trial, J Clin Oncol; MRD2STOP study; PERSEUS maintenance update
Looking Ahead: Living with Hope and Science
- Reframe the Definition of "Cure": Do not be disheartened by the classical "incurable" label. A "Functional Cure"—where the disease remains undetectable for decades and your daily life is vibrant and uninterrupted—is now a tangible reality.
- Prioritize Deep, Sustained Responses: Partner with your medical team to choose modern quadruplet induction, optimize stem cell harvest, and periodically assess bone marrow and imaging MRD.
- Leverage Modern Immunotherapies Early: Groundbreaking innovations like CAR T-cell therapies and bispecific antibodies are no longer just last-line salvage tools—they are moving into earlier lines to establish durable, treatment-free survivorship.
Multiple myeloma has entered an era of precision medicine and long-term functional curability. Armed with rigorous science, advanced diagnostics, and cutting-edge treatments, patients and families have more reason than ever to look to the future with strength and optimism.
This article is compiled by China Myeloma Development Network (CMDN - ChinaMyeloma.org) based on peer-reviewed literature and international clinical practice guidelines. It is intended for educational purposes only and does not constitute medical advice. Please consult your hematologist or treating oncology team for personalized clinical guidance.
FAQs
- Can multiple myeloma be completely cured today?
- Under traditional strict definitions, myeloma is still managed as a chronic, incurable disease. However, modern oncology focuses on achieving a 'Functional Cure'—suppressing cancer cells to undetectable levels so patients enjoy decades of normal, active life without symptoms or active progression.
- If my lab tests are completely normal and I reached Complete Response (CR), am I cured?
- Not necessarily. A standard Complete Response means no visible cancer cells appear on standard blood, urine, or marrow smear tests, but millions of microscopic cells may still remain. This is why sustained deep MRD negativity is required to ensure long-term disease control.
- What exactly is a 'Functional Cure'?
- A Functional Cure means your residual cancer cells are dormant and harmless, your organs (bones and kidneys) remain healthy, and you enjoy a normal lifespan and excellent quality of life. Under medical supervision, some patients can even achieve treatment-free intervals.
- What does 'Sustained MRD Negativity' mean and why is it crucial?
- It means achieving undetectable residual disease at a sensitivity of 1 in 100,000 (10⁻⁵) or 1 in 1,000,000 (10⁻⁶) in the bone marrow along with negative PET-CT scans, maintained across at least two consecutive tests spaced 12 months apart. It is the single strongest predictor of decade-long survival.
- Do patients with high-risk genetic abnormalities still have hope for a functional cure?
- Yes. Landmark clinical evidence demonstrates that achieving and sustaining deep MRD negativity completely overcomes the negative prognostic impact of high-risk cytogenetics like del(17p) or t(4;14), allowing high-risk patients to achieve survival rates comparable to standard-risk patients.
- Can I ever safely stop taking my medications?
- Stopping maintenance therapy is becoming feasible for selected patients who achieve sustained multi-year MRD negativity. However, treatment cessation should strictly occur within structured clinical trials or under the close direction of a myeloma specialist with ongoing monitoring.
Related reading
References used for this guide
- NCCN Guidelines v5.2026, Multiple Myeloma
- Chinese Guidelines for the Diagnosis and Management of Multiple Myeloma (2024 Revision)
- International Myeloma Working Group (IMWG) Consensus Criteria for Response and Minimal Residual Disease
- PERSEUS: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- MAIA: Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Myeloma
- CARTITUDE-4: Cilta-cel vs Standard Care in Lenalidomide-Refractory Multiple Myeloma
for their academic support:
for myeloma patients globally